PriceTargets.com logo

Allena Pharmaceuticals - ALNA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 12/13/2023 01:00 AM ET
+0 (0.00%)
Get New Allena Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALNA

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Allena Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ALNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Allena Pharmaceuticals. This rating has held steady since March 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/22/2022B. RileyDowngradeBuy ➝ Neutral$3.00
3/21/2022HC WainwrightReiterated RatingBuy ➝ Neutral
3/21/2022LADENBURG THALM/SH SHReiterated RatingBuy ➝ Neutral
1/24/2022B. RileyLower Target$4.00 ➝ $3.00
8/18/2021B. RileyLower TargetBuy$5.00 ➝ $4.00
8/11/2021HC WainwrightBoost TargetBuy$10.00 ➝ $11.00
10/1/2020B. RileyBoost TargetBuy$4.00 ➝ $5.00
9/10/2020WedbushReiterated RatingBuy$18.00
9/10/2020HC WainwrightReiterated RatingBuy
7/15/2020Roth CapitalReiterated RatingBuy ➝ Market Perform$11.00
7/15/2020LADENBURG THALM/SH SHReiterated RatingBuy$8.00
6/2/2020WedbushReiterated RatingBuy$26.00
6/1/2020HC WainwrightInitiated CoverageBuy$10.00
3/23/2020WedbushReiterated RatingBuy$26.00
3/18/2020Roth CapitalLower Target$31.00 ➝ $11.00
3/13/2020B. RileyLower TargetBuy$11.00 ➝ $7.00
2/17/2020Credit Suisse GroupReiterated RatingHold$4.00
2/12/2020B. RileyReiterated RatingBuy$11.00
2/12/2020WedbushReiterated RatingBuy$26.00
1/27/2020WedbushReiterated RatingBuy$26.00
(Data available from 12/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Allena Pharmaceuticals logo
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.07
Low: $0.02
High: $0.16

52 Week Range

Now: N/A

Volume

96,558 shs

Average Volume

15,688,501 shs

Market Capitalization

$37 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Allena Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Allena Pharmaceuticals in the last twelve months:
View the latest analyst ratings for ALNA.

What is the current price target for Allena Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Allena Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Allena Pharmaceuticals in the next year.
View the latest price targets for ALNA.

What is the current consensus analyst rating for Allena Pharmaceuticals?

Allena Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ALNA.

What other companies compete with Allena Pharmaceuticals?

Other companies that are similar to Allena Pharmaceuticals include TRACON Pharmaceuticals, Genocea Biosciences, Genocea Biosciences, Eloxx Pharmaceuticals and Amgen. Learn More about companies similar to Allena Pharmaceuticals.

How do I contact Allena Pharmaceuticals' investor relations team?

Allena Pharmaceuticals' physical mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company's listed phone number is (617) 467-4577 and its investor relations email address is [email protected]. The official website for Allena Pharmaceuticals is www.allenapharma.com. Learn More about contacing Allena Pharmaceuticals investor relations.